Neurodevelopmental outcomes in children with PHACE syndrome

Cheryl L. Brosig, Dawn H. Siegel, Anita Haggstrom, Ilona J. Frieden, Beth A. Drolet

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Practitioners who work with children with posterior fossa, facial hemangiomas, arterial anomalies, cardiovascular anomalies, and abnormalities of the eye (PHACE) syndrome need information about neurodevelopmental outcomes to provide appropriate anticipatory guidance and education for parents. This study aimed to determine the neurodevelopmental outcomes in children with PHACE syndrome and identify which children may be at greatest risk for delays. Methods: Children with a diagnosis of PHACE syndrome (ages 4–18 yrs) were recruited from the PHACE Syndrome International Clinical Registry and Genetic Repository. Participants (n = 25) underwent a neurodevelopmental evaluation at a children's hospital tertiary care referral center between 2009 and 2013. Children completed standardized neurocognitive tests assessing multiple domains. Parents completed standardized questionnaires assessing behavioral and emotional functioning. Results: Results were analyzed according to cohort and individual subject. Mean scores for the cohort did not differ significantly from test norms in most domains. The only subtest that the cohort scored lower on than test norms was Word Structure, a language task. Forty-four percent of the sample scored within the normal range in all domains, 28% had one score in the at-risk range (1–2 standard deviations [SDs] below the mean), 12% had two or more scores in the at-risk range, and 16% had at least one score in the impaired range (>2 SDs below the mean). Conclusion: Although most children in this cohort of patients with PHACE syndrome did not have significant neurodevelopmental deficits, a subset of patients had delays in multiple areas. Practitioners who work with these children should routinely ask about neurocognitive and developmental skills. Children with more severe phenotypes should be referred for appropriate evaluations and intervention services.

Original languageEnglish (US)
Pages (from-to)415-423
Number of pages9
JournalPediatric Dermatology
Volume33
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

Tertiary Care Centers
Parents
Cardiovascular Abnormalities
Hemangioma
Registries
Reference Values
Language
Phenotype
Education
Surveys and Questionnaires

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Brosig, C. L., Siegel, D. H., Haggstrom, A., Frieden, I. J., & Drolet, B. A. (2016). Neurodevelopmental outcomes in children with PHACE syndrome. Pediatric Dermatology, 33(4), 415-423. https://doi.org/10.1111/pde.12870

Neurodevelopmental outcomes in children with PHACE syndrome. / Brosig, Cheryl L.; Siegel, Dawn H.; Haggstrom, Anita; Frieden, Ilona J.; Drolet, Beth A.

In: Pediatric Dermatology, Vol. 33, No. 4, 01.07.2016, p. 415-423.

Research output: Contribution to journalArticle

Brosig, CL, Siegel, DH, Haggstrom, A, Frieden, IJ & Drolet, BA 2016, 'Neurodevelopmental outcomes in children with PHACE syndrome', Pediatric Dermatology, vol. 33, no. 4, pp. 415-423. https://doi.org/10.1111/pde.12870
Brosig, Cheryl L. ; Siegel, Dawn H. ; Haggstrom, Anita ; Frieden, Ilona J. ; Drolet, Beth A. / Neurodevelopmental outcomes in children with PHACE syndrome. In: Pediatric Dermatology. 2016 ; Vol. 33, No. 4. pp. 415-423.
@article{d9d3c337037c424aa3a1f77b0ce9e91b,
title = "Neurodevelopmental outcomes in children with PHACE syndrome",
abstract = "Background: Practitioners who work with children with posterior fossa, facial hemangiomas, arterial anomalies, cardiovascular anomalies, and abnormalities of the eye (PHACE) syndrome need information about neurodevelopmental outcomes to provide appropriate anticipatory guidance and education for parents. This study aimed to determine the neurodevelopmental outcomes in children with PHACE syndrome and identify which children may be at greatest risk for delays. Methods: Children with a diagnosis of PHACE syndrome (ages 4–18 yrs) were recruited from the PHACE Syndrome International Clinical Registry and Genetic Repository. Participants (n = 25) underwent a neurodevelopmental evaluation at a children's hospital tertiary care referral center between 2009 and 2013. Children completed standardized neurocognitive tests assessing multiple domains. Parents completed standardized questionnaires assessing behavioral and emotional functioning. Results: Results were analyzed according to cohort and individual subject. Mean scores for the cohort did not differ significantly from test norms in most domains. The only subtest that the cohort scored lower on than test norms was Word Structure, a language task. Forty-four percent of the sample scored within the normal range in all domains, 28{\%} had one score in the at-risk range (1–2 standard deviations [SDs] below the mean), 12{\%} had two or more scores in the at-risk range, and 16{\%} had at least one score in the impaired range (>2 SDs below the mean). Conclusion: Although most children in this cohort of patients with PHACE syndrome did not have significant neurodevelopmental deficits, a subset of patients had delays in multiple areas. Practitioners who work with these children should routinely ask about neurocognitive and developmental skills. Children with more severe phenotypes should be referred for appropriate evaluations and intervention services.",
author = "Brosig, {Cheryl L.} and Siegel, {Dawn H.} and Anita Haggstrom and Frieden, {Ilona J.} and Drolet, {Beth A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/pde.12870",
language = "English (US)",
volume = "33",
pages = "415--423",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Neurodevelopmental outcomes in children with PHACE syndrome

AU - Brosig, Cheryl L.

AU - Siegel, Dawn H.

AU - Haggstrom, Anita

AU - Frieden, Ilona J.

AU - Drolet, Beth A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Practitioners who work with children with posterior fossa, facial hemangiomas, arterial anomalies, cardiovascular anomalies, and abnormalities of the eye (PHACE) syndrome need information about neurodevelopmental outcomes to provide appropriate anticipatory guidance and education for parents. This study aimed to determine the neurodevelopmental outcomes in children with PHACE syndrome and identify which children may be at greatest risk for delays. Methods: Children with a diagnosis of PHACE syndrome (ages 4–18 yrs) were recruited from the PHACE Syndrome International Clinical Registry and Genetic Repository. Participants (n = 25) underwent a neurodevelopmental evaluation at a children's hospital tertiary care referral center between 2009 and 2013. Children completed standardized neurocognitive tests assessing multiple domains. Parents completed standardized questionnaires assessing behavioral and emotional functioning. Results: Results were analyzed according to cohort and individual subject. Mean scores for the cohort did not differ significantly from test norms in most domains. The only subtest that the cohort scored lower on than test norms was Word Structure, a language task. Forty-four percent of the sample scored within the normal range in all domains, 28% had one score in the at-risk range (1–2 standard deviations [SDs] below the mean), 12% had two or more scores in the at-risk range, and 16% had at least one score in the impaired range (>2 SDs below the mean). Conclusion: Although most children in this cohort of patients with PHACE syndrome did not have significant neurodevelopmental deficits, a subset of patients had delays in multiple areas. Practitioners who work with these children should routinely ask about neurocognitive and developmental skills. Children with more severe phenotypes should be referred for appropriate evaluations and intervention services.

AB - Background: Practitioners who work with children with posterior fossa, facial hemangiomas, arterial anomalies, cardiovascular anomalies, and abnormalities of the eye (PHACE) syndrome need information about neurodevelopmental outcomes to provide appropriate anticipatory guidance and education for parents. This study aimed to determine the neurodevelopmental outcomes in children with PHACE syndrome and identify which children may be at greatest risk for delays. Methods: Children with a diagnosis of PHACE syndrome (ages 4–18 yrs) were recruited from the PHACE Syndrome International Clinical Registry and Genetic Repository. Participants (n = 25) underwent a neurodevelopmental evaluation at a children's hospital tertiary care referral center between 2009 and 2013. Children completed standardized neurocognitive tests assessing multiple domains. Parents completed standardized questionnaires assessing behavioral and emotional functioning. Results: Results were analyzed according to cohort and individual subject. Mean scores for the cohort did not differ significantly from test norms in most domains. The only subtest that the cohort scored lower on than test norms was Word Structure, a language task. Forty-four percent of the sample scored within the normal range in all domains, 28% had one score in the at-risk range (1–2 standard deviations [SDs] below the mean), 12% had two or more scores in the at-risk range, and 16% had at least one score in the impaired range (>2 SDs below the mean). Conclusion: Although most children in this cohort of patients with PHACE syndrome did not have significant neurodevelopmental deficits, a subset of patients had delays in multiple areas. Practitioners who work with these children should routinely ask about neurocognitive and developmental skills. Children with more severe phenotypes should be referred for appropriate evaluations and intervention services.

UR - http://www.scopus.com/inward/record.url?scp=84978174389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978174389&partnerID=8YFLogxK

U2 - 10.1111/pde.12870

DO - 10.1111/pde.12870

M3 - Article

C2 - 27291925

AN - SCOPUS:84978174389

VL - 33

SP - 415

EP - 423

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 4

ER -